The 2024 Alzheimer’s Association’s International Conference (AAIC) annual conference (https://aaic.alz.org/) will take place July 28 – August 1, 2024 in Philadelphia, PA. The NGI Center is represented by 11 of our own researchers who are showcasing their recent work on Alzheimer’s disease either through oral presentations, guided poster tours, and posters. The contributions to this […]
Category: News
NeuroGenomics and Informatics Pilot Grant Program 2024 awardees
We are excited to announce the winners of the NeuroGenomics and Informatics (NGI) Pilot Grant Program 2024, a funding initiative aimed at supporting research leveraging multi-omic approaches to understand the biology of neurodegenerative diseases For more information about the Pilot Awards please see: NGI Pilot Grant | NGI | WUSTL We are delighted to award […]
Assistant Professor Position-Tenure Track and other positions Open!
The NeuroGenomics and Informatics (NGI) Center (https://neurogenomics.wustl.edu/) at Washington University School of Medicine, seeks to appoint Full-time tenure-track faculty position with interdisciplinary research interests and approaches that focus on improving our understanding of Alzheimer Disease and related dementias. Candidates should have an interest in generating and/or leveraging multi-omic data to understand the biology of neurodegeneration […]
Pilot Grant Submissions Requested!
The Neurogenomics and Informatics (NGI) Center (https://neurogenomics.wustl.edu/) is requesting proposals for the 2024 pilot grant program. Projects may involve one or more collaborating laboratories. The Project PI must be an NGI-affiliated member. As a pilot grant, we do not intend to fund ongoing projects, but rather projects to develop preliminary results for future grant submissions or […]
NGI pilot leads to a large NIH-funding to study endolysosomal diseases
The NGI Center funded a pilot project to Drs. Dickson, Cooper and Sardiello to Monitoring Lysosomal Content and Signaling in Lysosomal Storage Disorders. This funding led to a larger collaborative NIH funding for more than $8 million. This collaborative effort, which combines the areas of pediatrics, genetics, bioinformatics, and psychiatry will lead scientists to understand […]
NGI Center at AD/PD 2023
The Alzheimer’s Disease/Parkinson’s disease (AD/PD) 2023 annual conference (https://adpd.kenes.com/) begins tomorrow and will continue through Saturday, April 1. The virtual conference provides 6 full days of scientific presentations and symposia including a mix of pre-recorded oral presentations and live discussions with presenters.The Cruchaga lab is represented by 13 of our own researchers who are presenting […]
2023 Pilot Grant
The Neurogenomics and Informatics (NGI) Center (https://neurogenomics.wustl.edu/) is requesting proposals for a new pilot grant program. The vision of the NGI is to transform the field of human neurogenomics by going beyond the analysis of genomic DNA to explore other omics layers, including epigenomics, transcriptomics, proteomics, and metabolomics. Molecular phenotyping of human samples is instrumental […]
NGI Pilot Grant
The Neurogenomics and Informatics (NGI) Center (https://neurogenomics.wustl.edu/) is requesting proposals for a new pilot grant program. The vision of the NGI is to transform the field of human neurogenomics by going beyond the analysis of genomic DNA to explore other omics layers, including epigenomics, transcriptomics, proteomics, and metabolomics. Molecular phenotyping of human samples is instrumental […]
NGI at the AAIC
The Alzheimer’s Association International Conference (AAIC 2021) is underway virtually as well as in-person in Denver, Colorado. The hybrid conference started Monday and continues through Friday July 30. Sessions at the meeting focus on clinical treatment and research of Alzheimer disease including biomarkers, disease prevention and treatment, social determinants, and genetics of the disease. This […]
Largest Brain and CSF pQTL Analysis Published in Nature Neuroscience
Chengran Yang, a PhD candidate in the lab of Carlos Cruchaga, is the first author of a manuscript just published in the prestigious journal Nature Neuroscience. He used multi-tissue proteomics to identify hundreds of proteins that are genetically regulated. By using statistical methods, such as Mendelian randomization, he was able to implicate several of these […]
The NGI is Well Represented at the 2021 AD/PD Conference
The Alzheimer’s Disease/Parkinson’s disease (AD/PD) annual conference began yesterday and will continue through Sunday, March 14. The virtual conference provides 6 full days of scientific presentations and symposia including a mix of pre-recorded oral presentations and live discussions with presenters. The NGI is represented by 10 of our own researchers who are presenting their recent […]
Workshop: Application of Machine Learning Tools to Omics in Neuroscience
The NGI will be hosting a Workshop on the “Application of Machine Learning Tools to Omics in Neuroscience” on February 18, 2021. This full-day, virtual event will feature basic introductory sessions on Machine Learning, plenary lectures by invited speakers, oral presentations of submitted abstracts, and a round table discussion. Everyone is invited to register by […]
MS4A4A is the major regulator of TREM2 levels
Drs. Harari, Benitez, Karch and Cruchaga leveraged biospecimens obtained from large and well-characterized human cohorts to identify a novel protective gene for Alzheimer disease, MS4A4A, that is also the major regulator of TREM2. This study provides a strong evidence of a biological link between TREM2 and MS4A4A in microglia in the context of AD. However, […]
Drs. Cruchaga and Karch receive new funding to advance personalized medicine in Alzheimer Disease
Drs. Cruchaga and Karch are some of the Washington University investigators that received funding from Centene to perform molecular phenotyping of Alzheimer’s cases to identify novel molecular biomarkers and the identification of novel therapeutically targets. Specifically we plan to develop a personalized medicine approach to understand the effects of Alzheimer’s disease risk genes by combining […]
Using Genetics to predict risk for AD at individual level (Links to an external site)
Dr. Cruchaga discuss about the use of polygenic risk scores to predict individual level risk for Alzheimer and provide this data “direct-to-consumer”.
Mendelian Neurodegenerative mutations and 23&me (Links to an external site)
In collaboration with Alzforum Dr. Cruchaga analyses the impact of direct-to-consumer genetic testing.
Our work presented at the AAIC2017 was highlighted by Alzforum (Links to an external site)
Geneticists are inventing new ways to hunt AD variants that went undetected in GWAS and might shed light on AD pathogenesis. Many labs are searching for polymorphisms tied to specific quantitative traits. As Yuetiva Deming from Carlos Cruchaga’s group at Washington University, St. Louis, pointed out, GWAS identify risk variants but say nothing about how that risk manifests